Nonsteroidal anti-inflammatory drugs (NSAIDs): Progress in small molecule drug development

Pharmaceuticals

Volumn 3, Issue 5, 2010, Pages 1530-1549

  Rao, Praveen P N ^a   Kabir, Saad N ^a   Mohamed, Tarek ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Lp PLA2; mPGES 1; NSAIDs; Small molecules; TNF

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; APRICOXIB; CELECOXIB; CIMICOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DARAPLADIB; DICLOFENAC; IBUPROFEN; INDOMETACIN; INDOMETACIN DERIVATIVE; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NAPROXEN; NIMESULIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SB 222657; SB 435495; SC 75416; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARESPLADIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NONHUMAN; PAIN; PRESCRIPTION; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

EID: 77954897606     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3051530     Document Type: Article

References (94)

1. Vane, J. R. The fight against rheumatism: From willow bark to COX-1 sparing drugs. J. Physiol. Pharmacol. 2000, 51, 573-586.
2. Marnett, L. J. The COXIB experience: A look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 265-290.
3. Inotai, A.; Hanko, B.; Meszaro, A. Trends in the non-steroidal anti-inflammatory drug market in six central-eastern european countries based on retail information. Pharmacoepidemiol. Drug Saf. 2010, 19, 183-190.
4. Meade, E. A.; Smith, W. L.; DeWitt, D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1993, 268, 6610-6614.
5. Talley, J. J. Selective inhibitors of cyclooxygenase-2 (COX-2). Prog. Med. Chem. Res. 1999, 36, 201-234.
6. Black, W. C. Selective cycloxygenase-2 inhibitors. Annu. Rep. Med. Chem. 2004, 39, 125-138.
7. Penning, T. D.; Talley, J. J.; Bertenshaw, S.R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4- methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
8. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Zamboni, R. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2- inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
9. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. 1996, 3, 927-933.
10. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644-648.
11. Mitchell, J. A.; Warner, T. D. COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat. Rev. Drug Discov. 2006, 5, 75-85.
12. Zhang, J. J.; Ding, E. L.; Song, Y. Q. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events-meta-analysis of randomized trials. JAMA 2006, 296, 1619-1632.
13. Smith, T. J. Cyclooxygenases as the principle target for the action of NSAIDs. Rheum. Clinics N. Amer. 1998, 24, 501-523.
14. Fourie, A. M. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. Curr. Opin. Investig. Drugs 2009, 10, 1173-1182.
15. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5- LOX) as a new strategy to provide safer nonsteroidal anti-inflammatory drugs. Eur. J. Med. Chem. 2003, 38, 645-659.
16. Poeckel, D.; Funk, C. D. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc. Res. 2010, 86, 243-253.
17. Wang, D.; Dubois, R. N. Prostaglandins and cancer. Gut 2006, 55, 115-122.
18. Cha, Y. I.; Dubois, R. N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med. 2007, 58, 239-252.
19. Palladino, M. A.; Bahjat, F. R.; Theodorakis, E. A.; Moldaver, L. L. Anti-TNF-therapies: The next generation. Nat. Rev. Drug Disc. 2003, 2, 736-746.
20. Seruga, B.; Zhang, H.; Bernstein, L. J.; Tannock, I. F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 2008, 8, 887-899.
21. Craft, J. M.; Watterson, D. M.; Van Eldik, L. J. Neuroinflammation: A potential therapeutic target. Expert Opin. Ther. Targets 2005, 9, 887-900.
22. Muller, N. COX-2 inhibitors as antidepressants and antipsychotics: Clinical evidence. Curr. Opin. Invest. Drugs 2010, 11, 31-42.
23. Rainsford, K. D. Anti-inflammatory drugs in the 21st century. Subcell. Biochem. 2007, 42, 3-27.
24. Wallace, J. L.; Ignarro, L. J.; Fiorucci, S. Potential cardioprotective actions of NO-releasing aspirin. Nat. Rev. Drug Discov. 2002, 1, 375-382.
25. Bernstein, P. Chemistry and structure-activity relationships of leukotriene receptor antagonists. Am. J. Respir. Crit. Care Med. 1998, 157, S220-S226.
26. Ruschitzka, F. T.; Wenger, R. H.; Stallmach, T.; Quaschning, T.; de Wit, C.; Wagner, K.; Labugger, R.; Kelm, M.; Noll, G.; Rülicke, T.; Shaw, S.; Lindberg, R. L.; Rodenwaldt, B.; Lutz, H.; Bauer, C.; Lüscher, T. F.; Gassmann, M. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. USA 2000, 97, 11609-11613.
27. Muscara, M. N.; McNight, W.; Del Soldato, P.; Wallace, J. L. Effects of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Pharmacol. Lett. 1998, 62, 235-240.
28. Bandarage, U. K.; Chen, L.; Fang, X.; Garvey, D. S.; Glavin, A.; Janero, D. R.; Letts, L. G.; Mercer, G. J.; Saha, J. K.; Schroeder, J. D.; Shumway, M. J.; Tam, S. W. Nitrosothiol esters of diclofenac: Synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J. Med. Chem. 2000, 43, 4005-4016.
29. Fitzhugh, A. L.; Keefer, L. K. Diazeniumdiolates: pro- and antioxidant applications of the NONOates. Free Radic. Biol. Med. 2000, 28, 1463-1469.
30. Velázquez, C. A.; Rao, P. N. P.; Knaus, E. E. Novel nonsteroidal anti-inflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. 2005, 48, 4061-4067.
31. Velázquez, C. A.; Chen, Q. H.; Citro, M. L.; Keefer, L. K.; Knaus, E. E. Second-generation aspirin and indomethacin prodrugs possessing an O2-(acetoxymethyl)-1-(2-carboxypyrrolidin-1- yl)diazenium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. 2008, 51, 1954-1961.
32. Chegaev, K.; Lazzarato, L.; Tosco, P.; Cena, C.; Marini, E.; Rolando, B.; Carrupt, P. A.; Fruttero, R.; Gasco, A. NO-donor COX-2 inhibitors: New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J. Med. Chem. 2007, 50, 1449-1457.
33. Wey, S. J.; Augustyniak, M. E.; Cochran, E. D.; Ellis, J. L.; Fang, X.; Garvey, D. S.; Janero, D. R.; Letts, L. G.; Martino, A. M.; Melim, T. L.; Murty, M. G.; Richardson, S. K.; Schroeder, J. D.; Selig, W. M.; Trocha, A. M.; Wexler, R. S.; Young, D. V., Zemtseva, I. S.; Zifcak, B. M. Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J. Med. Chem. 2007, 50, 6367-6382.
34. Lazzarato, L.; Donnola, M.; Rolando, B.; Marini, E.; Cena, C.; Coruzzi, G.; Guaita, E.; Morini, G.; Fruttero, R.; Gasco, A.; Biondi, S. Searching for new NO-donor aspirin-like molecules: A new class of nitrooxy-acyl derivatives of salicylic acid. J. Med. Chem. 2008, 51, 1894-1903.
35. Moriarty, L. M.; Lally, M. N.; Carolan, C. G.; Jones, M.; Clancy, J. M.; Gilmer, J. F. Discovery of a true aspirin prodrug. J. Med. Chem. 2008, 51, 7991-7999.
36. Lazzarato, L.; Donnola, M.; Rolando, B.; Chegaev, K.; Marini, E.; Cena, C.; Di Stilo, A.; Fruttero, R.; Biondi, S.; Ongini, E.; Gasco, A. (Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins. J. Med. Chem. 2009, 52, 5058-5068.
37. Rao, P. N. P.; Rajesh, K. G. Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer. IDrugs 2009, 12, 711-722.
38. Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Forli, S.; Rovini, M.; Cappelli, A.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Vivoli, E.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Anzini, M. Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity. J. Med. Chem. 2007, 50, 5403-5411.
39. Anzini, M.; Rovini, M.; Cappelli, A.; Vomero, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Giordani, A.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Biava, M. Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole 3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. J. Med. Chem. 2008, 51, 4476-4481.
40. Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Manetti, F.; Botta, M.; Forli, S.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Galeotti, N.; Makovec, F.; Giordani, A.; Anzellotti, P.; Patrignani, P.; Anzini, M. Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as anti-inflammatory and analgesic agents: Synthesis and in vitro and in vivo biological evaluation. J. Med. Chem. 2010, 53, 723-733.
41. Gierse, J.; Nickols, M.; Leahy, K.; Warner, J.; Zhang, Y.; Cortes-Burgos, L.; Carter, J.; Seibert, K.; Masferrer, J. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur. J. Pharmacol. 2008, 588, 93-98.
42. Renard, J. F.; Arslan, D.; Garbacki, N.; Pirotte, B.; de Leval, X. Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors. J. Med. Chem. 2009, 52, 5864-5871.
43. Swarbrick, M. E.; Beswick, P. J.; Gleave, R. J.; Green, R. H.; Bingham, S.; Bountra, C.; Carter, M. C.; Chambers, L. J.; Chessell, I. P.; Clayton, N. M.; Collins, S. D.; Corfield, J. A.; Hartley, C. D.; Kleanthous, S.; Lambeth, P. F.; Lucas, F. S.; Mathews, N.; Naylor, A.; Page, L. W.; Payne, J. J.; Pegg, N. A.; Price, H. S.; Skidmore, J.; Stevens, A. J.; Stocker, R.; Stratton, S. C.; Stuart, A. J.; Wiseman, J. O. Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 4504-4508.
44. Beswick, P. J.; Blackaby, A. P.; Bountra, C.; Brown, T.; Browning, K.; Campbell, I. B.; Corfield, J.; Gleave, R. J.; Guntrip, S. B.; Hall, R. M.; Hindley, S.; Lambeth, P. F.; Lucas, F.; Mathews, N.; Naylor, A.; Player, H.; Price, H. S.; Sidebottom, P. J.; Taylor, N. L.; Webb, G.; Wiseman, J. Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approach. Bioorg. Med. Chem. Lett. 2009, 19, 4509-4514.
45. Ramalho, T. C.; Rocha, M. V. J.; Da Cunna, E. F. F.; Freitas, M. P. The search for new COX-2 inhibitors: A review of 2002-2008 patents. Expert Opin. Ther. Patents 2009, 19, 1193-1228.
46. Reddy, M. V. R.; Billa, V. K.; Pallela, V. R.; Mallireddigari, M. R.; Boominathan, R.; Gabriel, J. L.; Reddy, E. P. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3- trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg. Med. Chem. 2008, 16, 3907-3916.
47. Geronikaki, A. A.; Lagunin, A. A.; Hadjipavlou-Litina, D. I.; Eleftheriou, P. T.; Filimonov, D. A.; Poroikov, V. V.; Alam, I.; Saxena, A. K. Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition. J. Med. Chem. 2008, 51, 1601-1609.
48. Dailey, L A.; Imming, P. 12-Lipoxygenase: Classification, possible therapeutic benefits from inhibition and inhibitors. Curr. Med. Chem. 1999, 6, 389-398.
49. Chowdhury, M. A.; Abdellatif, K. R.; Dong, Y.; Das, D.; Yu, G.; Velázquez, C. A.; Suresh, M. R.; Knaus, E. E. Synthesis and biological evaluation of salicylic acid and N-acetyl-2- carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg. Med. Chem. 2009, 19, 6855-6861.
50. Chowdhury, M. A.; Abdellatif, K. R.; Dong, Y.; Das, D.; Suresh, M. R.; Knaus, E. E. Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: Biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. J. Med. Chem. 2009, 52, 1525-1529.
51. Yu, G.; Chowdhury, M. A.; Abdellatif, K. R.; Dong, Y.; Rao, P. N. P.; Das, D.; Velázquez, C. A.; Suresh, M. R.; Knaus, E. E. Phenylacetic acid regioisomers possessing a N-difluoromethyl-1,2- dihydropyrid-2-one pharmacophore: Evaluation as dual inhibitors of cyclooxygenases and 5- lipoxygenase with anti-inflammatory activity. Bioorg. Med. Chem. 2010, 20, 896-902.
52. Chen, C. S.; Tan, C. M.; Huang, C. H.; Chang, L. C.; Wang, J. P.; Cheng, F. C.; Chern, J. W. Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-alpha production. Bioorg. Med. Chem. 2010, 18, 597-604.
53. Balsinde, J.; Balboa, M. A.; Insel, P. A.; Dennis, E. A. Regulation and inhibition of phospholipase A2. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 175-189.
54. Blank, M. L.; Lee, T.; Fitzgerald, V.; Snyder, F. A specific acetylhydrolase for 1-alkyl-2-acetylsn- glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J. Biol. Chem. 1981, 256, 175-178.
55. Berliner, J. A.; Subbanagounder, G.; Leitinger, N.; Watson, A.D.; Vora, D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc. Med. 2001, 11, 142-147.
56. Tjoelker, L. W.; Eberhardt, C.; Unger, J.; Trong, H. L.; Zimmerman, G. A.; McIntyre, T. M.; Stafforini, D. M.; Prescott, S. M.; Gray, P. W. Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J. Biol. Chem. 1995, 270, 25481-25487.
57. Macphee, C. H.; Nelson, J.; Zalewski, A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr. Opin. Pharmacol. 2006, 6, 154-161.
58. Tjoelker, L. W.; Wilder, C.; Eberhardt, C.; Stafforini, D. M.; Dietsch, G.; Schimpf, B.; Hooper, S.; Le Trong, H.; Cousens, L. S.; Zimmerman, G. A.; Yamadat, Y.; McIntyre, T. M.; Prescot, S. M.; Gray, P. W. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995, 374, 549-553.
59. Tellis, C. C.; Tselepsis, A. D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim. Biophys. Acta 2009, 1791, 327-338.
60. Caslake, M. J.; Packard, C. J. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat. Rev. Cardiol. 2005, 2, 529-535.
61. Wilensky, R. L.; Shi, Y.; Mohler, E. R.; Hamamdzic, D.; Burgert, M. E.; Li, J.; Postle, A.; Fenning, R. S.; Bollinger, J. G.; Hoffman, B. E.; Pelchovitz, D. J.; Yang, J.; Mirabile, R. C.; Webb, C. L.; Zhang, L.; Zhang, P.; Gelb, M. H.; Walker, M. C.; Zalewski, A.; Macphee, C. H. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 2008, 14, 1059-1066.
62. Zalewski, A.; Nelson, J. J.; Hegg, L.; Macphee, C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 923-931.
63. Shi, Y.; Zhang, P.; Zhang, L.; Osman, H.; Mohler, E. R.; Macpheec, C.; Zalewski, A.; Postle, A.; Wilensky, R. L. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 2007, 191, 54-62.
64. Zalewski, A.; Nelson, J. J.; Heg, J. J. Macphee, C. Lp-PLA2: A new kid on the block. Clin. Chem. 2006, 52, 1645-1649.
65. Lee, K. L.; Foley, M. A.; Chen, L.; Behnke, M. L.; Lovering, F. E.; Kirincich, S. J.; Wang, W.; Shim, J.; Tam, S.; Shen, M. W.; Khor, S.; Xu, X.; Goodwin, D. G.; Ramarao, M. K.; Nickerson- Nutter, C.; Donahue, F.; Ku, M. S.; Clark, J. D.; McKew, J. C. Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2α. J. Med. Chem. 2007, 50, 1380-1400.
66. Suckling, K. E. Phospholipase A2 inhibitors in the treatment of atherosclerosis: A new approach moves forward in the clinic. Expert Opin. Investig. Drugs. 2009, 18, 1425-1430.
67. Rosenson, R. S.; Hislop, C.; McConnell, D.; Elliott, M.; Stasiv, Y.; Wang, N., Waters, D. D. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): A phase II double-blind, randomized, placebo-controlled trial. Lancet 2009, 373, 649-658.
68. Corson, M. A.; Phospholipase A2 inhibitors in atherosclerosis: The race is on. Lancet 2009, 373, 608-610.
69. Tew, D. G.; Boyd, H. F.; Ashman, S.; Theobald, C.; Leach, C. A. Mechanism of inhibition of LDL phospholipase A2 by monocyclic beta-lactams: Burst kinetics and the effect of stereochemistry. Biochemistry 1998, 37, 10087-10093.
70. Blackie, J. A.; Bloomer, J. C.; Brown, M. J.; Cheng, H. Y.; Hammond, B.; Hickey, D. M.; Ife, R. J.; Leach, C. A.; Lewis, V. A.; Macphee, C. H.; Milliner, K. J.; Moores, K. E.; Pinto, I. L.; Smith, S. A.; Stansfield, I. G.; Stanway, S. J.; Taylor, M. A.; Theobald, C. J. The identification of clinical candidate SB-480848: A potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg. Med. Chem. Lett. 2003, 13, 1067-1070.
71. Leach, C. A.; Smith, S. A. N-Substituted pyridinone and pyrimidinone derivatives for use as Lp- PLA2 inhibitors in the treatment atherosclerosis. World Patent 2003, WO 03/086400, 1-33.
72. Mohler, E. R.; Ballantyne, C. M.; Davidson, M. H.; Hanefeld, M.; Ruilope, L. M.; Johnson, J. L.; Zalewski, A. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 2008, 51, 1632-1641.
73. Rosenson, R. S. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther. 2009, 23, 93-101.
74. McCullough, P. A. Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr. Atherosclerosis Rep. 2009, 11, 334-337.
75. Jakobsson, P. J.; Morgenstern, R.; Mancini, J.; Ford-Hutchinson, A.; Persson, B. Common structural features of MAPEG-A widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci. 1999, 8, 689-692.
76. Jakobsson, P. J.; Thorén, S.; Morgenstern, R.; Samuelsson B. Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA 1999, 96, 7220-7225.
77. Samuelsson, B.; Morgenstern, R.; Jakobsson, P. J. Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol. Rev. 2007, 59, 207-224.
78. Friesen, R. W.; Mancini, J. A. Microsomal prostaglandin E2 synthase-1 (mPGES-1): A novel antiinflammatory therapeutic target. J. Med. Chem. 2008, 51, 4059-4067.
79. Jegerschoeld, C.; Pawelzik, S.-C.; Purhonen, P.; Bhakat, P.; Gheorghe, K. R.; Gyobu, N.; Mitsuoka, K.; Morgenstern, R.; Jakobsson, P. J.; Hebert, H. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc. Natl. Acad. Sci. USA 2009, 105, 11110-11115.
80. Riendeau, D.; Aspiotis, R.; Ethier, D.; Gareau, Y.; Grimm, E. L.; Guay, J.; Guiral, S.; Juteau, H.; Mancini, J. A.; Méthot, N.; Rubin, J.; Friesen, R. W. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg. Med. Chem. Lett. 2005, 15, 3352-3355.
81. Côté, B.; Boulet, L.; Brideau, C.; Claveau, D.; Ethier, D.; Frenette, R.; Gagnon, M.; Giroux, A.; Guay, J.; Guiral, S.; Mancini, J.; Martins, E.; Massé, F.; Méthot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 6816-6820.
82. Giroux, A.; Boulet, L.; Brideau, C.; Chau, A.; Claveau, D.; Côté, B.; Ethier, D.; Frenette, R.; Gagnon, M.; Guay, J.; Guiral, S.; Mancini, J.; Martins, E.; Massé, F.; Méthot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 5837-5841.
83. Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5- lipoxygenase. J. Med. Chem. 2008, 51, 8068-8076.
84. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-650.
85. Keller, H.; Devchand, P. R.; Perroud, M.; Wahli, W. PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol. Chem. 1997, 378, 651-655.
86. Liedtke, A. J.; Keck, P. R.; Lehmann, F.; Koeberle, A.; Werz, O.; Laufer, S. A. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J. Med. Chem. 2009, 52, 4968-4972.
87. Rörsch, F.; Wobst, I.; Zettl, H.; Schubert-Zsilavecz, M.; Grösch, S.; Geisslinger, G.; Schneider, G.; Proschak, E. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. J. Med. Chem. 2010, 53, 911-915.
88. Wang, J.; Limburg, D.; Carter, J.; Mbalaviele, G.; Gierse, J.; Vazquez, M. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template. Bioorg. Med. Chem. Lett. 2010, 20, 1604-1609.
89. Foxwell, B.; Andreakos, E.; Brennan, F.; Feldmann, M.; Smith, C.; Conron, M. Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Ann. Rheum. Dis. 2003, 62, ii90-ii93.
90. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at proteinprotein interfaces. Nature 2007, 450, 1001-1009.
91. Taylor, P. C. The future of TNF-α antagonism. Future Rheumatol. 2007, 2, 233-236.
92. He, M. M.; Smith, A. S.; Oslob, J. D.; Flanagan, W. M.; Braisted, A. C.; Whitty, A.; Cancilla, M. T.; Wang, J.; Lugovskoy, A. A.; Yoburn, J. C.; Fung, A. D.; Farrington, G.; Eldredge, J. K.; Day, E. S.; Cruz, L. A.; Cachero, T. G.; Miller, S. K.; Friedman, J. E.; Choong, I. C.; Cunningham, B. C. Small-molecule inhibition of TNF-alpha. Science 2005, 310, 1022-1025.
93. Man, H. W.; Schafer, P.; Wong, L. M.; Patterson, R. T.; Corral, L. G.; Raymon, H.; Blease, K.; Leisten, J.; Shirley, M. A.; Tang, Y.; Babusis, D. M.; Chen, R.; Stirling, D.; Muller, G. W. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3- dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J. Med. Chem. 2009, 52, 1522-1524.
94. Chan, D. S.; Lee, H. M.; Yang, F.; Che, C. M.; Wong, C. C. L.; Abagyan, R.; Leung, C. H.; Ma, D. L. Structure-based discovery of natural-product-like TNF-α inhibitors. Angew. Chem. Int. Ed. 2010, 49, 2860-2864.